The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. All interested researchers with novel concepts are eligible to apply. PREVENT is not a grant program, but allocates NCI contract resources and expertise to generate data and materials, which are used by the applicants for further development. PREVENT’s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.
Read more About PREVENT.
Application Instructions
Effective November 2024, the PREVENT application submission deadlines will move to the first Monday in November and May.
The next submission deadline is Monday, November 4, 2024.
Please apply using the PREVENT Application System.
Supported Projects
132 Projects from PREVENT Cycles 1 through 24:
- 79 Chemoprevention projects
- 44 Immunoprevention projects
- 9 Biomarker projects
Read more about supported projects and supported prevention approaches.
Available Resources
- Efficacy
- Toxicology
- Regulatory Support
- Current Good Manufacturing Practice (CGMP)
- DCP Repository
Program Administration
- Governance Structure
- Technology Transfer Considerations
News and Events
DCP Participation at American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024
Date Posted: March 12, 2024
DCP/PREVENT-funded Project Presentations at the 2024 AACR Annual Meeting
Date Posted: March 12, 2024
Immune Interception Approaches for Individuals at Risk for Pancreatic Cancer
Date Posted: December 13, 2023
Chief, Chemopreventive Agent Development Research Group Position Available
Date Posted: August 21, 2023
DCP/PREVENT-funded Project Presentations at the 2023 AACR Annual Meeting
Date Posted: April 28, 2023